Copertina

Dose-adjusted treatment with 7-day venetoclax plus azacitidine or decitabine in patients with acute myeloid leukaemia

Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Steiner, Laurenz (Autore) , Silva Bermudez, Lina Susana (Autore) , Ghazal, Mahmoud (Autore) , Abba, Mohammed L. (Autore) , Gerhards, Catharina (Autore) , Metzgeroth, Georgia (Autore) , Fabarius, Alice (Autore) , Klein, Stefan (Autore) , Kreil, Sebastian (Autore) , Schmitt, Nanni (Autore) , Wuchter, Patrick (Autore) , Hofmann, Wolf-Karsten (Autore) , Streuer, Alexander (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 30 July 2026
In: European journal of haematology
Year: 2026, Pages: 1-11
ISSN:1600-0609
DOI:10.1111/ejh.70279
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ejh.70279
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.70279
Testo
Note sull'autore:Laurenz Steiner, Lina S. Silva-Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf-Karsten Hofmann, Alexander Streuer
Descrizione
Riassunto:Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle. Best overall response rate was 76% and did not differ significantly between schedules (p = 0.38). Median overall survival (OS) was numerically longer with 7d (28.4 months) than with 14d (11.4 months) or > 14d (6.7 months), although unadjusted differences were not significant (p = 0.23). At cycle level, the 7d schedule was associated with fewer infections and more complication-free cycles than both longer schedules, while bleeding events were similar. Grade 4 cytopenias and platelet transfusion requirements were also lower with 7d. In an adjusted Cox model, prior HMA exposure, non-favourable ELN 2024 risk and age ≥ 75 years were associated with inferior OS, whereas the 7d schedule remained associated with improved OS versus > 14d (HR 0.33, p = 0.03). Higher recent grade 4 neutropenia burden was independently associated with inferior OS. These findings suggest that abbreviated VEN exposure may improve tolerability without clear loss of efficacy in AML patients ineligible for intensive chemotherapy.
Descrizione del documento:Gesehen am 18.08.2026
Descrizione fisica:Online Resource
ISSN:1600-0609
DOI:10.1111/ejh.70279

Documenti analoghi